drugset / Trial / NCT01133613

Double-Blind, Randomized, Single Dose Escalation Safety Study of Intraarticular Bone Morphogenic Protein (38A BMP-7) in Subjects With Osteoarthritis (OA) of the Knee

NCT01133613

Phase 1 Completed 51 enrolled Stryker Biotech
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The objective of the study is to determine the safety and tolerability of two different formulations of BMP-7 for the treatment of osteoarthritis of the knee.

Timeline

Start
2010-05
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Bone morphogenetic protein 7 Unknown 0.03 mg/ml Other
Subject Bone morphogenetic protein 7 Unknown 0.1 mg/ml Other
Subject Bone morphogenetic protein 7 Unknown 0.3 mg/ml Other

Indications